top of page

A single failed Phase II trial costs $15M+ 

Clinical programs with genetics evidence are 2–3x more likely to succeed*. Variantt makes these insights accessible without a full genetics department.

​

Discover how genetics evidence can de-risk your pipeline

​

*Based on Minikel et al., Nature 2024​​

Most drugs fail in Phase II. Genetics could change that.

  • 7 out of 10 Phase 2 clinical trials fail.

  • 50% of failures are due to efficacy.

  • Many failures begin with the wrong target, a decision made at the very start of discovery.

  • Each phase II failure can cost $50M or more and years of effort.

Our solution

Variantt delivers trusted genetics evidence to help drug discovery teams choose the right targets

Aggregates and integrates multiple high-quality datasources

Provides full data provenance for confidence and reproducibility

Offers causal evidence to validate targets

To hear more about what we're building for you please book a call.

Designed for drug discovery scientists - not just bioinformatics experts

bottom of page